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Abstract
This document provides guidance for the risk assessment under Regulation (EC) No 1829/2003 of the
unintended, adventitious or technically unavoidable presence in food and feed of low level of
genetically modiﬁed plant material intended for markets other than in the European Union. In this
context, the presence at low level is deﬁned to be maximum 0.9% of genetically modiﬁed plant
material per ingredient. This guidance is intended to assist applicants by indicating which scientiﬁc
requirements of Annex II of Regulation (EU) No 503/2013 are considered necessary for the risk
assessment of the presence at low levels of genetically modiﬁed plant material in food and feed.
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Summary
Following a request of the European Commission, the European Food Safety Authority (EFSA)
provides guidance on the scientiﬁc requirements of Annex II of Regulation (EU) No 503/2013
considered necessary (and those not) to conclude on the safety of applications covering the adventitious
or technically unavoidable presence at low level (0.9% or below per ingredient) of genetically modiﬁed
plant material in food and feed intended for markets other than in the European Union (EU).
This guidance provides support to and should be read in conjunction with Regulation (EU)
No 503/2013 and it is not intended to serve as a stand-alone guidance.
The characterisation of the transformation event and of its intended effects should be performed.
Not all the scientiﬁc requirements of the Annex II of Regulation (EU) No 503/2013 aiming at
identifying unintended effects are considered necessary on a routine basis, since the safety and
nutritional impact of these effects on the ingredient are considered limited in the context of the
presence of a genetically modiﬁed plant material at low level. These requirements include some data
concerning the expression of the insert, in silico RNAi off–target searches, routine comparative analysis
studies of the genetically modiﬁed plant; 90-day toxicity studies in rodents on the whole food and feed
are not considered necessary.
On a case-by-case basis, when a hypothesis can be formulated for compositional changes that may
impact the safety and nutritional characteristics of the ingredient, a targeted compositional analysis is
requested. The experimental design, selection of endpoints and data analysis of such a targeted
analysis would not need to follow all the scientiﬁc requirements of Annex II of Regulation (EU)
No 503/2013. Comparative compositional studies performed according to Codex Alimentarius could
support such assessment.
The applicant needs to justify the approach followed and to indicate what assumptions have been
made during the risk assessment as well as the nature and magnitude of uncertainties.
Both acute and repeated exposure scenarios should be envisaged.
The possible cumulative contribution to an ingredient from various genetically modiﬁed plants and
derived products present at low level and showing similar traits should be considered.
Environmental risk assessments conducted under situations of the presence at low levels should
follow the principles and approach outlined in the Genetically Modiﬁed Organisms Panel Guidance
Document on the environmental risk assessments of genetically modiﬁed plants and other applicable
EFSA guidelines.
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1. Introduction
1.1. Background and Terms of Reference as provided by the requestor
Genetically modiﬁed organisms (GMOs) and derived food and feed products are subject to a risk
assessment and regulatory approval before they can enter the market in the EU. In this process, the
role of the EFSA is to independently assess and scientiﬁcally advise risk managers on any possible risk
that the use of GMOs may pose to human’s and animal’s health and the environment. EFSA’s scientiﬁc
advice is elaborated by its GMO Panel with the scientiﬁc support of speciﬁc working groups and EFSA
scientists.
Detailed guidance was adopted by EFSA (2006) and updated in EFSA GMO Panel (2011a) to assist
applicants in the preparation and the presentation of applications of food and feed from genetically
modiﬁed (GM) plants submitted under Regulation (EC) No 1829/20031 (Reg. (EC) 1829/2003) and
hereafter referred to as ‘standard GMO applications’. The European Commission subsequently adopted
in April 2013 Regulation (EU) No 503/20132 (Reg. (EU) 503/2013) on applications for authorisation of
GM food and feed. Annex II of this Regulation lists the scientiﬁc requirements to be provided for GM
plants for food and feed uses in accordance with Articles 5(3) and 17(3) of Reg. (EC) 1829/2003.
Article 5(2) of Reg. (EU) 503/2013 states that by way of derogation, an application may be submitted
that does not satisfy all the scientiﬁc requirements for the risk assessment of GM food and feed set out
in Annex II, provided that ‘particular information is not necessary owing to the nature of the genetic
modiﬁcation or of the product; or it is not scientiﬁcally necessary, or technically possible to supply such
information’.
Genetically modiﬁed organisms and derived food and feed products not intended to be exported to
the EU have been or are being developed for speciﬁc health or market needs in third countries. The
accidental presence of some of these GMOs at low levels cannot completely be excluded in exports to the
EU. In this context and in accordance with Article 29 of Regulation (EC) No 178/2002,3 the European
Commission in 2014 mandated EFSA to advise whether or not all requirements of Annex II to
Reg. (EU) 503/2013 are necessary to conclude on the safety of applications covering the unintended
presence of GMOs in food and feed at the adventitious or technically unavoidable level of 0.9% or below.
If not, EFSA was required to indicate which requirements are unnecessary and to give the underlying
rationale. Following a request for clariﬁcation by EFSA, the European Commission further explained that:
• the EFSA guidance should be applicable to the presence at low level of GMOs, independently
of the existence or not of a third country risk assessment;
• applications submitted under this EFSA guidance should only concern GMOs developed for
speciﬁc health or market needs in third countries and not intended for the EU market.
Therefore, they should not cover GMOs for which a full scope application has been previously
submitted;
• exposure scenarios through commodities, such as grains, beans, or through foods consumed
whole and undiluted should be considered under this EFSA guidance (further clariﬁcation on
this point is provided in Section 1.2 of this document);
• a cumulative risk assessment should be performed in case of similar traits present in the same
crop in different applications submitted under this EFSA guidance;
• for stacks, the same principles as those referred to in Reg. (EU) 503/2013 will apply and the
implementation of the 0.9% threshold should follow the same rules as for labelling purposes,
i.e. the threshold applies to individual events.
In 2015, EFSA accepted the mandate from the European Commission and committed to issue an EFSA
Scientiﬁc Opinion providing guidance on which scientiﬁc requirements of Annex II of Reg. (EU) 503/2013
are necessary to conclude on the safety of applications submitted under Reg. (EC) 1829/2003 covering
the unintended presence of GMOs in food and feed at the adventitious or technically unavoidable
presence of 0.9% or below, and which are not, providing the underlying rationale.
1 Regulation (EC) No Reg. 1829/2003 of the European Parliament and of the Council of 22 September 2003 on genetically
modiﬁed food and feed. Ofﬁcial Journal of the European Communities, L 268, 1–23.
2 Commission Implementing Regulation (EU) No 503/2013 of 3 April 2013 on applications for authorisation of genetically
modiﬁed food and feed in accordance with Regulation (EC) No Reg. 1829/2003 of the European Parliament and of the Council
and amending Commission Regulations (EC) No 641/2004 and (EC) No 1981/2006. OJ L 157, 8.6.2013, p. 1–48.
3 Regulation (EC) No 178/2002 of the European Parliament and of the Council of 28 January 2002 laying down the general
principles and requirements of food law, establishing the European Food Safety Authority and laying down procedures in
matters of food safety. OJ L 031, 1.2.2002, p. 1–24.
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1.2. Interpretation of the Terms of Reference
Following an exchange with the European Commission, it was further clariﬁed that an application of
a GMO at low level submitted under Reg. (EC) 1829/2003 (hereafter referred to as ‘LL application’)
covers a request for the authorisation of a GMO4 present at a level of maximum 0.9% per ingredient
in any food and/or feed, due to adventitious or technically unavoidable circumstances.
For the purpose of this document, an ingredient (hereafter referred to as ‘LL ingredient’) is the
mixture of the GMO subject of the LL application and the same plant species and/or derived product at
the predeﬁned proportion of a maximum of 0.9% and minimum of 99.1%, respectively.
It is assumed that in a LL application the GMO is present at a level of maximum 0.9% per
LL ingredient from point of entry into the EU through the food/feed production and processing chain,
up to the food (or feed) portion consumed.
Situations where a GMO can achieve levels higher than 0.9% per LL ingredient are therefore not in
the remit of this guidance. This could be the case of GM fruits and vegetables (e.g. papaya, potatoes)
constituting either a full portion or part of a consumed portion resulting in an exposure of consumers
(or animals) to that GMO higher than 0.9%. Therefore, even if included in the European Commission
mandate, these situations are not within the remit of this guidance.
The decision on whether a given GMO can constitute a LL application is a risk management issue,
and it is therefore not in the remit of this guidance.
In its mandate, the European Commission referred to Codex Alimentarius guideline for the food
safety assessment of Low Level Presence (LLP) of recombinant DNA plant material in food5 as a
document to consider during the development of this guidance. The GMO Panel took into consideration
principles and requirements outlined in the above-mentioned document to develop this guidance.
Some adaptations were needed to address the Terms of Reference of this mandate; these are
summarised in Appendix A of this guidance.
2. Data and methodologies
2.1. Data
In delivering this guidance, the GMO Panel took into account the requirements outlined in
Reg. (EC) 1829/2003, Reg. (EU) 503/2013, Codex Alimentarius (2009),6 EFSA guidance documents
(EFSA GMO Panel, 2010, 2011a) and relevant scientiﬁc publications.
2.2. Methodologies
EFSA established an ad hoc Working Group of the GMO Panel to address the mandate on the
risk assessment of the presence at low levels of GMOs not intended for the EU market in imported
food and feed under the frame of Reg. (EC) 1829/2003. In accordance with the Terms of Reference
of the mandate, the Working Group scrutinised which scientiﬁc requirements of Annex II of
Reg. (EU) 503/2013 are necessary to conclude on the safety of GMOs present in food and feed at the
adventitious or technically unavoidable level of maximum 0.9% per ingredient. Possible derogations
from existing requirements were identiﬁed, and justiﬁed reasons provided.
In order to adequately take EU Member States and stakeholders comments into account, two
consultations were organised in a stepwise manner. The ﬁrst consultation (from 28 October to
9 December 2016) was dedicated to EU Member States. Following this consultation process, the
document was revised by the GMO Panel and then opened for a second public consultation (from
2 May to 13 June 2017) where all stakeholders, including EU Member States, contributed further to
the development of the guidance. As an outcome of these consultations, a technical report will be
published on the EFSA website.
4 Genetically modiﬁed plants for food or feed uses, food or feed containing or consisting of genetically modiﬁed plants and food
or feed produced from such plants in accordance with Reg. (EU) 503/2013 (Preamble 5).
5 Annex 3 (Food safety assessment in situations of low-level presence of recombinant-DNA plant material in food - adopted
2008) of the Guideline for the conduct of food safety assessment of foods derived from recombinant-DNA Plants, CAC/GL
45-2003, adopted 2003 (Codex Alimentarius, 2009).
6 Codex Alimentarius, 2009 includes the Guideline for the conduct of food safety assessment of foods derived from recombinant-
DNA Plants, CAC/GL 45-2003, adopted 2003; and its Annex 3 Food safety assessment in situations of low-level presence of
recombinant-DNA plant material in food adopted in 2008.
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3. Assessment
3.1. Introduction
3.1.1. Scope of the guidance
This document is intended to assist applicants in the preparation of LL applications by indicating
which scientiﬁc requirements of Annex II of Reg. (EU) 503/2013 are necessary and which are not, in
this case providing justiﬁcation, in order to conclude on the safety of a GMO not intended for the EU
market present at low level in any food/feed (maximum 0.9% per ingredient). This document supports
Reg. (EU) 503/2013 and it is not intended to serve as a stand-alone guidance.
Deﬁnitions and requirements of Reg. (EU) 503/2013 other than those indicated in its Annex II
apply to LL applications.
This guidance does not cover the risk assessment of GMOs for cultivation purposes, GM
microorganisms, GM animals, GMOs for non-food/feed uses and novel foods as this is not in the scope of
Reg. (EU) 503/2013. This guidance does not consider issues related to risk management (e.g. traceability,
labelling and coexistence). Socioeconomic and ethical issues are also outside the scope of this guidance.
3.1.2. General considerations for the risk assessment of LL applications
The risk assessment strategy for standard GMO applications is driven by the comparative assessment
principle, which aims to evaluate whether the GMO is as safe and as nutritious as traditionally cultivated
crops (and derived products) with a history of safe use for consumers and/or animals (Codex
Alimentarius, 2009; EFSA GMO Panel, 2011a). Within this comparative frame, a standard GMO application
is assessed assuming the possibility of a 100% replacement of the corresponding conventional crop and
derived products. To support the assessment, the GMO Panel identiﬁed the scientiﬁc requirements and
deployed a wide range of tools and methods (EFSA GMO Panel, 2011a), which have been incorporated
into Annex II of Reg. (EU) 503/2013 by the European Commission and EU Member States.
In a LL situation as deﬁned in this guidance, exposure to the GMO will be at maximum 0.9% per
LL ingredient. This predeﬁned threshold implies a lower exposure to the GMO than that foreseen in
standard GMO applications. The adventitious or technically unavoidable circumstances leading to a
LL situation do not exclude the possibility of repeated exposure of consumers/animals to the GMO.
Therefore, both single and repeated exposure scenarios are considered.
Based on the above considerations and taking into account the Codex Alimentarius guideline for the
‘Food safety assessment in situations of low-level presence of recombinant-DNA plant material in food’
(Annex 3, adopted 2008), the GMO Panel considers that certain scientiﬁc requirements for the risk
assessment of standard GMO applications are necessary in LL situations, others are not or should be
adapted. Section 3.2 of this guidance describes in detail which scientiﬁc requirements of Annex II of
Reg. (EU) 503/2013 are necessary and which are not to conclude on the safety of a GMO in a LL application.
For the risk assessment of LL applications of stacked events, the applicant will provide a risk
assessment of each single transformation event or, in accordance with Article 3(6) of Reg. (EU) 503/2013,
refer to already submitted application(s).
3.2. Scientiﬁc requirements for the risk assessment of LL applications
submitted under Reg. (EC) 1829/2003 (Reg. [EU] 503/2013;
Annex II)
3.2.1. Introduction: Deﬁnitions (Reg. [EU] 503/2013; Annex II.I, 1)
Paragraph 1 of Annex II.I of Reg. (EU) 503/2013 applies.
3.2.2. Introduction: Speciﬁc considerations (Reg. [EU] 503/2013; Annex II.I, 2)
3.2.2.1. Insertion of marker genes and other nucleic acid(s) sequences not essential to
achieve the desired trait (Reg. [EU] 503/2013; Annex II.I, 2.1)
All the scientiﬁc requirements described in paragraph 2.1 of Annex II.I of Reg. (EU) 503/2013 are
considered necessary for LL applications.
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3.2.2.2. Risk assessment of genetically modiﬁed food and feed containing stacked
transformation events (Reg. [EU] 503/2013; Annex II.I, 2.2)
The risk assessment of GMOs containing stacked transformation events (i.e. single transformation
events combined by conventional crossing, also referred hereafter as stacks) described in
paragraph 2.2 of Annex II.I of Reg. (EU) 503/2013 focuses on:
a) stability of the transformation events;
b) expression of the transformation events;
c) potential synergistic or antagonistic effects resulting from the combinations of the transformation
events in accordance with the respective sections of Annex II.II of Reg. (EU) 503/2013 relative
to toxicology (Section 1.4), allergenicity (Section 1.5) and nutritional assessment (Section 1.6).
The scientiﬁc requirements to address the above points are provided in the speciﬁc Molecular
characterisation and Food and feed sections of Annex II.II of Reg. (EU) 503/2013. The relevance of
these requirements for LL applications is discussed in the respective speciﬁc sections of this document.
The scientiﬁc requirements laid down in paragraph 2.2 of Annex II.I of Reg. (EU) 503/2013 as
regards the assessment of subcombinations in stacked events are considered necessary in
LL applications.
3.2.3. Scientiﬁc requirements: Hazard identiﬁcation and characterisation
(Reg. [EU] 503/2013; Annex II.II, 1)
3.2.3.1. Information relating to the recipient or (where appropriate) to parental plants
(Reg. [EU] 503/2013; Annex II.II, 1.1)
All the scientiﬁc requirements described in paragraph 1.1 of the Annex II.II of Reg. (EU) 503/2013
are considered necessary in LL applications.
3.2.3.2. Molecular characterisation (Reg. [EU] 503/2013; Annex II.II, 1.2)
The molecular characterisation of the GM plant serves two purposes: ﬁrst, it allows the
characterisation of the transformation event, and second, it is the ﬁrst step to detect potential
unintended effects linked to the genetic modiﬁcation.
In the case of LL situations, the exposure to the GMO is deﬁned to be at a maximum 0.9% per
ingredient, and therefore, some of the molecular characterisation data requirements speciﬁed in
Annex II.II of Reg. (EU) 503/2013 are not considered necessary, or necessary only on a case-by-case
basis. In the following sections, the rationale for considering whether speciﬁc requirements are
necessary or not is described.
Information relating to the genetic modiﬁcation (Reg. [EU] 503/2013; Annex II.II, 1.2.1, subsections
1.2.1.1–1.2.1.3)
The scientiﬁc requirements of this paragraph (including all subsections) serve to characterise the
genetic modiﬁcation(s) of the plant. Therefore, all requirements described in paragraph 1.2.1 of
Annex II.II of Reg. (EU) 503/2013 are considered necessary in LL applications.
Information relating to the genetically modiﬁed plant (Reg. [EU] 503/2013; Annex II.II, 1.2.2,
subsections 1.2.2.1–1.2.2.5)
The scientiﬁc requirements in subsection 1.2.2.1 (‘General description of the trait[s] and
characteristics which have been introduced or modiﬁed’) and subsection 1.2.2.2 (‘Information on the
sequences actually inserted/deleted’) of Annex II.II of Reg. (EU) 503/2013 serve to characterise the
genetic modiﬁcation(s) and therefore are considered necessary in LL applications.
Subsection 1.2.2.3 (‘Information on the expression of the insert[s]’) of Annex II.II of
Reg. (EU) 503/2013 describes the scientiﬁc requirements as regards the information on the expression
of the insert(s). These requirements serve to demonstrate whether the inserted/modiﬁed sequence
results in the intended changes in the GM plant.
Protein expression data obtained under the conditions in which the crop is grown as well as the
description of the methods used for expression analyses (point 1.2.2.3(a)] and (e)) are considered
necessary for characterising the GM plants in LL applications on single transformation events. However,
only the expression levels from those part(s) of the plant used for food and feed purposes are
considered needed to complete the risk assessment. Therefore, points 1.2.2.3(b) (‘information on
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developmental expression of the insert during the life cycle of the plant’) and 1.2.2.3(c) (‘parts of the
plant where the inserted/modiﬁed sequences are expressed’) of Annex II of Reg. (EU) 503/2013 are
not considered necessary in LL applications. The likelihood of off-target effects resulting from silencing
approaches by RNAi expression large enough to raise safety concerns in a LL situation is considered
negligible. Therefore, the in silico search for potential ‘off-target gene(s)’ described in point 1.2.2.3(e)
is not considered necessary.
The requirements described in subsection 1.2.2.3 (‘Information on the expression of the insert[s]’)
of Annex II.II of Reg. (EU) 503/2013 also serve to characterise the potential unintended expression of
new open reading frames (ORFs) identiﬁed as raising a safety concern. Point 1.2.2.3 (d) requiring such
an expression analysis is considered necessary in a LL situation.
In the case of stacks, the GMO Panel considers that the likelihood for changes in the expression
levels of the newly inserted sequences as a consequence of interactions between the events impacting
the safety of the LL ingredient is negligible, given the deﬁned presence of 0.9% of the stack per
LL ingredient. Therefore, point 1.2.2.3(f) of Annex II of Reg. (EU) 503/2013 is not routinely required.
On a case-by-case basis, when the nature or the characterisation of the transformation events
combined in a stack suggests an interaction that may result in changes of the expression levels of the
newly inserted sequences raising safety concerns in a LL situation, these data should be provided.
The scientiﬁc requirements in subsection 1.2.2.4 (‘Genetic stability of the insert and phenotypic
stability of the genetically modiﬁed plant’) of Annex II.II of Reg. (EU) 503/2013 serve to characterise
the genetic modiﬁcation(s) of the plant and are considered necessary in LL applications.
The scientiﬁc requirements in subsection 1.2.2.5 (‘Potential risk associated with horizontal gene
transfer’) of Annex II.II of Reg. (EU) 503/2013 are considered necessary in LL applications.
Conclusions of the molecular characterisation (Reg. [EU] 503/2013; Annex II.II, 1.2.3)
Based on the above, this section should contain concluding information on the molecular
characterisation of the transformation event(s) as well as indications on whether the genetic
modiﬁcation(s) raises safety concerns considering the scope of the LL application.
3.2.3.3. Comparative analysis (Reg. [EU] 503/2013, Annex II. II, 1.3)
The comparative analysis of composition and agronomic and phenotypic characteristics constitutes,
together with the molecular characterisation, the starting point to structure and conduct the risk
assessment of food and feed from GM plants under Reg. (EC) 1829/2003 (EFSA GMO Panel, 2011a). It
aims at identifying the differences in composition (intended and unintended) between the GM plant
and its conventional counterpart, and between the food and feed derived from the GM plant and those
derived from the conventional counterpart. It also aims at identifying differences in agronomic
performance and phenotypic characteristics (intended and unintended) between the GM plant and its
conventional counterpart. The methodological approach to conduct the comparative assessment on
GMOs is detailed in paragraph 1.3 of Annex II.II of Reg. (EU) 503/2013, including criteria for the
selection of appropriate comparator, experimental design of ﬁeld trials and statistical analysis of
results, selection of endpoints to measure and effects of processing.
The GMO Panel considers that the scientiﬁc requirements on comparative analysis of
Reg. (EU) 503/2013 can be adapted for LL applications. Since in LL situations the level of exposure of
consumers and animals to the GMO is deﬁned to be at a maximum 0.9% per LL ingredient, not all
differences identiﬁed in the comparative analysis may be relevant.
As regards compositional analysis, the level of a compound in a LL ingredient is determined by the
levels of such compound in the GMO and in the plant (and/or derived product) constituting the remaining
part of the LL ingredient. The ratio between these two levels determines the extent to which the level of
the compound of the GMO impacts the overall level of that compound in the LL ingredient. For example,
if the level of a compound in the GMO is 100X larger than that of the ingredient without the GMO, the
increase of the compound in the LL ingredient as compared to the ingredient without that GMO is
approximately twofold (~ 1.891).7 A decrease in the level of a compound in the GMO results into a level in
the LL ingredient never lower than 0.991 folds with respect to the ingredient without the GMO. In
Table 1, other examples of how the 0.9% GMO can affect the overall level of a compound in a LL
ingredient are shown.
7 If the level of a compound (A) in the GMO is 100X compared to the level of A in the ingredient without the GMO, then the
level of A in the LL ingredient = 100 9 0.9% + 99.1% = 189.1% = 1.891 folds with respect to level of A in the ingredient
without the GMO.
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On the basis of current knowledge, the GMO Panel is of the opinion that variations in the level of
compound(s) in GMOs are generally not large enough to impact the nutritional or safety characteristics
of an ingredient in LL situations, with the possible exception of GMOs with traits developed to improve
nutrition (e.g. nutritionally enhanced crops, Perez-Massot et al., 2013; EFSA GMO Panel, 2014) or in
cases of expected unintended compositional changes (e.g. EFSA GMO Panel, 2011b).
Therefore, the GMO Panel considers that comparative compositional analysis in LL situations is only
necessary in any of the following cases:
• the intended trait targets the composition of the GMO (e.g. nutritionally enhanced GMOs);
• a hypothesis for a relevant compositional change can be formulated based on available
information from the hazard identiﬁcation, such as in the case of unintended compositional
changes anticipated by the precedent analyses;
• if new constituents, other than newly expressed protein(s), are produced in the GMO.
In these cases, a targeted comparative compositional analysis is needed to quantify differences of
the GMO with respect to its conventional counterpart, conﬁrming the hypothesis that triggered the
analysis. The outcome of the analysis will be used to perform an exposure assessment and to provide
information relevant for cumulative risk assessment (see Section 3.2.5.3 of this guidance).
When there is the expectation of interactions between the transformation events stacked by
conventional crossing that could lead to compositional changes in the stack GMO possibly impacting
the composition of the LL ingredient, experimental targeted compositional analysis is needed.
The inclusion of agronomic and phenotypic endpoints in the comparative assessment studies in
Reg. (EU) 503/2013 is intended to identify unintended effects related to the genetic modiﬁcation and
to address plant biology and agronomic traits. Considering that the main objective of comparative
analysis in the context of LL situations is to quantify target compositional differences in the GMO with
respect to its conventional counterpart conﬁrming the hypothesis that triggered the analysis, a
comparative analysis of agronomic and phenotypic characteristics described in paragraph 1.3.5 of
Annex II.II of Reg. (EU) 503/2013 is not considered necessary in the context of LL situations. On a
case-by-case basis, a comparative analysis of agronomic and phenotypic characteristics may be
needed to support the environmental risk assessment (ERA) (see Section 3.3 of this guidance).
Choice of conventional counterpart and additional comparators (Reg. [EU] 503/2013; Annex II.II, 1.3.1)
When a targeted comparative compositional analysis is needed, the scientiﬁc requirements laid down
in this paragraph of Annex II.II of Reg. (EU) 503/2013 are considered necessary in LL applications,
including requirements regarding stacks.
Experimental design and statistical analysis of data from ﬁeld trials for comparative analysis
(Reg. [EU] 503/2013; Annex II.II, 1.3.2, subsections 1.3.2.1, 1.3.2.2)
When a targeted comparative compositional analysis is needed, it should include a difference test in
accordance with the ‘Principles of experimental design’ described in point 1.3.2.1(a) of the subsection
Table 1: Impact of variations in the levels of a compound in a GMO on the level of the same
compound in a LL ingredient
Relative level of a compound in a GMO with
respect to the level of that compound in the
ingredient without that GMO
Relative level of the compound in the
LL ingredient with respect to the level of that
compound in the ingredient without that GMO
0 0.991
0.001 0.991009
0.01 0.99109
0.1 0.9919
1 1
10 1.081
20 1.171
50 1.441
90 1.801
100 1.891
200 2.791
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‘Description of the protocols for the experimental design’ of Annex II.II of Reg. (EU) 503/2013.
However, the GMO Panel considers that the test of equivalence is not necessary in LL situations. The
test of equivalence aims to verify whether the GM plant is equivalent or not to reference varieties,
apart from the introduced trait(s); estimation of natural ranges of variability of compositional endpoints
is of limited relevance in a LL situation since the focus is to quantify the level(s) of target compound(s)
in the GMO with respect to its conventional counterpart.
Regarding the ‘Speciﬁc protocols for experimental design’ detailed in point 1.3.2.1(b) of the above-
mentioned subsection of Annex II.II of Reg. (EU) 503/2013, the GMO Panel considers that when
needed, studies to obtain material for the targeted comparative compositional analysis should be
conducted under conditions maximising change(s) expected in the composition of the GMO, according
to the hypothesis triggering the analysis. Field trials and greenhouse studies could be ﬁt for such
purpose. This deviates from Reg. (EU) 503/2013, which always requires the performance of trials under
representative ﬁeld conditions. Furthermore, since in LL situations the estimation of equivalence limits is
not considered necessary, the inclusion of reference varieties in the experimental design is not required.
In case of ﬁeld trial studies, the number of sites to support the targeted comparative compositional
analysis in LL applications can be less than the eight prescribed by Reg. (EU) 503/2013 but should be
adequate to perform the subsequent risk assessment steps (i.e. exposure assessment and cumulative
risk assessment).
Similarly, in case the targeted comparative compositional analysis is performed under greenhouse
conditions, justiﬁcations for the speciﬁc conditions selected should be provided to demonstrate their
adequacy to perform subsequent risk assessment steps (i.e. exposure assessment and cumulative risk
assessment). Criteria used for the selection of speciﬁc study conditions (e.g. ﬁeld trials or greenhouse
studies) should be described and the choice scientiﬁcally and explicitly justiﬁed by the applicant.
All the other requirements detailed in point 1.3.2.1 (b) are considered necessary for both ﬁeld trials
and greenhouse studies.
The ‘Statistical analysis’ requirements laid down in subsection 1.3.2.2 of Annex II.II of Reg. (EU) 503/
2013 are needed for LL applications, with the exception of the equivalence test (as explained above).
Selection of material and compounds for analysis (Reg. [EU] 503/2013; Annex II.II, 1.3.3)
The requirements laid down in this paragraph of Annex II.II of Reg. (EU) 503/2013 are necessary
in LL applications. In particular, the targeted comparative analysis should be conducted on raw
agricultural commodities, with additional analysis of processed products conducted where appropriate,
on a case-by-case basis.
Comparative analysis of composition (Reg. [EU] 503/2013; Annex II.II, 1.3.4)
When a hypothesis triggering the requirement for speciﬁc compositional data is identiﬁed (see above),
the targeted analysis of these speciﬁc compounds should be performed. A justiﬁcation on the choice of
compound(s) should be provided. This differs from requirements of Reg. (EU) 503/2013, where the
minimum range of compounds to be analysed is that listed in the Organisation for Economic Cooperation
and Development (OECD) consensus documents on compositional considerations for new plant varieties.
Comparative analysis of agronomic and phenotypic characteristics (Reg. [EU] 503/2013; Annex II.II,
1.3.5)
The GMO Panel considers that a comparative analysis of agronomic and phenotypic characteristics
in general is not necessary in the context of LL situations, this differing from requirements of
paragraph 1.3.5 of Annex II.II of Reg. (EU) 503/2013 (see considerations above). On a case-by-case
basis, it may be needed to support the ERA (see Section 3.3).
Effects of processing (Reg. [EU] 503/2013; Annex II.II, 1.3.6)
The scientiﬁc requirements laid down in this paragraph of Annex II.II of Reg. (EU) 503/2013
regarding the assessment of the possible impact of the processing and/or preserving technologies on
the characteristics of the derived products of the GMO are considered necessary in LL applications.
Comparative assessment studies performed under non-EU regulatory frames: applicability in
LL applications
The GMO Panel considers that comparative assessment studies in accordance with Codex
Alimentarius (2009) could support the targeted comparative compositional analysis in LL situations,
provided that the relevant compositional endpoints, i.e. those of interest on the basis of the hypothesis
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triggering the analysis, have been reliably measured; and that all Codex Alimentarius (2009) principles
and requirements have been duly fulﬁlled.
In contrast, compositional analysis studies not aligned to requirements of Codex Alimentarius
(2009) are not considered appropriate by the GMO Panel.
Conclusions of the comparative analysis (Reg. [EU] 503/2013; Annex II.II, 1.3.7)
In LL applications, comparative compositional analysis is considered necessary when the
composition of the GMO is expected to impact on the nutritional or safety characteristics of the
LL ingredient. In these situations, a targeted compositional analysis is requested and adaptations of
the scientiﬁc requirements of Annex II.II Reg. (EU) 503/2013 as regards the experimental design,
selection of endpoints and data analysis are indicated. The applicant should state the rationale for
conducting the targeted compositional analysis, or justify why this was not conducted. When a
targeted comparative compositional analysis is conducted, the applicant is requested to provide
justiﬁcation for the conditions used; to indicate whether the outcome of the targeted compositional
analysis conﬁrms the expectations and allows to properly quantify differences between the GMO and
its conventional counterpart to perform the subsequent exposure assessment; to provide information
relevant for cumulative risk assessment; and to indicate if further investigations are needed.
3.2.3.4. Toxicology (Reg. [EU] 503/2013; Annex II.II, 1.4)
This section of Annex II.II Reg. (EU) 503/2013 requires assessing the toxicological impact of any
change on the whole GM food/feed resulting from the genetic modiﬁcation such as the introduction of
new genes, gene silencing or overexpression of endogenous genes.
More speciﬁcally, Annex II.II of the Reg. (EU) 503/2013 requires assessing:
– the toxicity of individual compounds, i.e. newly expressed proteins (paragraphs 1.4.1 and
1.4.5) and new constituents other than newly expressed proteins (paragraphs 1.4.2 and
1.4.5); and possible altered levels of food and feed constituents (paragraphs 1.4.3 and 1.4.5);
– the toxicity of the whole genetically modiﬁed food and feed (paragraphs 1.4.4 and 1.4.5).
Testing of newly expressed proteins (Reg. [EU] 503/2013; Annex II.II, 1.4.1)
The scientiﬁc requirements laid down in this paragraph of Annex II.II of the Reg. (EU) 503/2013
are considered necessary in LL applications.
Testing of new constituents other than proteins (Reg. [EU] 503/2013; Annex II.II, 1.4.2)
The scientiﬁc requirements laid down in this paragraph of Annex II.II of the Reg. (EU) 503/2013
are considered necessary in LL applications.
Information on altered levels of food and feed constituents (Reg. [EU] 503/2013; Annex II.II, 1.4.3)
When changes in the levels of speciﬁc constituents of the GMO (i.e. compositional endpoints)
possibly impacting the toxicological proﬁle of the LL ingredient are expected (see Section 3.2.3.3 of
this guidance), these should be analytically conﬁrmed and toxicologically assessed according to the
scientiﬁc requirements laid down in paragraph 1.4.3 of Annex II.II of Reg. (EU) 503/2013.
Testing of whole genetically modiﬁed food and feed (Reg. [EU] 503/2013; Annex II.II, 1.4.4
subsections 1.4.4.1–1.4.4.4)
In line with this paragraph of Reg. (EU) 503/2013 in LL situations the applicant should primarily
base its risk assessment of the GM food and feed on the molecular characterisation and toxicological
evaluation of the GMO, as above described. The GMO Panel considers that in LL situations a 90-day
feeding study as requested in subsection 1.4.4.1 of Annex II.II of Reg. (EU) 503/2013 (‘Testing of
whole GM food and feed’) is not needed to corroborate information on the toxicological characteristics
of the whole GM food and feed in rodents and/or to reduce the remaining uncertainties, considering
the limited exposure to the GMO. On a case-by-case basis, depending on the GMO characteristics and
on the results from preceding analysis, a 90-day study might be necessary to test speciﬁc toxicological
hypothesis. In line with subsections 1.4.4.2 and 1.4.4.3 of Annex II.II of Reg. (EU) 503/2013, animal
studies for reproductive and developmental toxicity testing or to examine the safety and the
characteristics of food and feed from the GMO in target species might be considered on a case-by-case
basis to test speciﬁc toxicological hypothesis. If animal studies are performed, the interpretation of
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their relevance should be conducted according to the scientiﬁc requirements laid down in subsection
1.4.4.4 of Annex II.II of Reg. (EU) 503/2013.
Conclusions of the toxicological assessment (Reg. [EU] 503/2013; Annex II.II, 1.4.5)
The requirements of Section 1.4 of Annex II.II of Reg. (EU) 503/2013 apply to the toxicological
assessment of newly expressed proteins and, when expected and analysed also to new constituents
(other than new proteins) and altered levels of constituents.
Requirements of Section 1.4 of Annex II.II of Reg. (EU) 503/2013 on animal feeding studies on the
whole food/feed apply in the case these were conducted.
3.2.3.5. Allergenicity (Reg. [EU] 503/2013; Annex II.II, 1.5)
Considerations and requirements of Annex II.II of Reg. (EU) 503/2013 relative to the allergenicity
assessment of the GMO refer to:
– assessment of allergenicity of newly expressed proteins and adjuvanticity (paragraphs 1.5.1, 1.5.3
and 1.5.4);
– assessment of allergenicity of the GM food or feed (paragraphs 1.5.2 and 1.5.4).
Assessment of allergenicity of newly expressed proteins (Reg. [EU] 503/2013; Annex II.II, 1.5.1)
Requirements laid down in paragraph 1.5.1 of Annex II.II of Reg. (EU) 503/2013 are considered
necessary in LL applications.
Assessment of allergenicity of the genetically modiﬁed food or feed (Reg. [EU] 503/2013;
Annex II.II, 1.5.2)
The GMO Panel considers that due to the maximum 0.9% contribution of the GMO to the
ingredient, requirements laid down in paragraph 1.5.2 of Annex II.II of Reg. (EU) 503/2013 are
considered not necessary on a routine basis (see considerations in Section 3.1.2 of this guidance).
However, in the case where there is the expectation of changes in the level of known endogenous
allergens in the GMO impacting the allergenicity of the LL ingredient, these endogenous allergens
should be analytically measured (see considerations in Section 3.2.3.3 of this guidance). In this case,
the assessment of allergenicity of the food or feed from the GMO should be conducted according to
requirements of paragraph 1.5.2 of Annex II.II of Reg. (EU) 503/2013.
Assessment of adjuvanticity (Reg. [EU] 503/2013; Annex II.II, 1.5.3)
Requirements laid down in paragraph 1.5.3 of Annex II.II of Reg. (EU) 503/2013 are considered
necessary in LL applications.
Conclusions of the allergenicity assessment (Reg. [EU] 503/2013; Annex II.II, 1.5.4)
Paragraph 1.5.4 of Annex II.II of Reg. (EU) 503/2013 applies for the allergenicity assessment of
newly expressed proteins. The assessment of the allergenicity of food or feed from the GMO should be
conducted in the case changes in the levels of endogenous allergens possibly impacting the
allergenicity of the LL ingredient are expected. In such situations, relevant identiﬁed endogenous
allergens should be analysed and the assessment should indicate whether the GMO could impact the
allergenicity of the LL ingredient.
3.2.3.6. Nutritional assessment (Reg. [EU] 503/2013; Annex II.II, 1.6)
Considering that the scope of LL applications is limited to a level of maximum 0.9% of a GMO per
LL ingredient, a nutritional assessment is not considered necessary on a routine basis (see
Section 3.1.2 of this guidance) unless changes in the levels of constituents (i.e. compositional
endpoints) in the GMO possibly impacting the nutritional characteristics of the LL ingredient are
expected (see Section 3.2.3.3 of this guidance). In this case, these constituents should be analysed
and nutritionally assessed. The GMO Panel considers that in such situation requirements of
paragraph 1.6.2 of Annex II.II of Reg. (EU) 503/2013 (‘Points to consider for the nutritional
assessment of genetically modiﬁed food and feed’) can be adapted as follows: point (a) the nutritional
assessment should be focused on hypothesis-driven target compounds, taking into account their levels
(see Section 3.2.3.3 of this guidance); point (b) should consider their bioavailability and biological
efﬁcacy; point (c) should consider the anticipated dietary intake of the ingredient without the GMO and
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the resulting nutritional impact of the GMO (at a maximum 0.9% incorporation) in the LL ingredient.
The assessment should include both acute and repeated dietary intake scenarios.
For LL situations concerning stacks, the applicant should provide an assessment of the potential
synergistic or antagonistic interactions between the events which may have a nutritional impact on the
LL ingredient.
Nutritional studies of genetically modiﬁed food (Reg. [EU] 503/2013; Annex II.I, 1.6.3) and feed
(Reg. [EU] 503/2013; Annex II.II, 1.6.4)
In line with Reg. (EU) 503/2013, on a case-by-case basis, depending on the GMO characteristics
and on the results from preceding analysis, nutritional studies on food and feed from the GMO might
be appropriate to test speciﬁc hypothesis.
In the case nutritional assessment studies are needed in a LL application, requirements laid down
in paragraphs 1.6.3 and 1.6.4 of Annex II.II of Reg. (EU) 503/2013 are considered necessary.
Conclusion of the nutritional assessment (Reg. [EU] 503/2013; Annex II.II, 1.6.5)
The conclusion of the nutritional assessment in a LL application should indicate if the GMO at
maximum 0.9% incorporation in a LL ingredient has a nutritional impact on the LL ingredient after
acute and repeated exposure.
3.2.3.7. Standardised guidelines for toxicity tests (Reg. [EU] 503/2013; Annex II.II, 1.7)
Section 1.7 of Annex II.II of Reg. (EU) 503/2013 applies.
3.2.4. Scientiﬁc requirements: Exposure assessment (Reg. [EU] 503/2013];
Annex II. II, 2)
In a LL application, the exposure to the GMO is deﬁned to be maximum 0.9% per ingredient, under
acute or repeated intake scenarios. The GMO Panel considers that the exposure assessment
requirements laid down in Annex II.II of Reg. (EU) 503/2013 should be based on this predetermined
exposure level.
In particular, exposure considerations should focus on newly produced components (e.g. newly
expressed proteins) and on constituent(s) showing levels altered enough to impact the nutritional or
safety characteristics of the ingredient (see Section 3.2.3.3 of this guidance).
3.2.5. Scientiﬁc requirements: Risk Characterisation (Reg. [EU] 503/2013;
Annex II.II, 3)
3.2.5.1. Issues to be considered for risk characterisation (Reg. [EU] 503/2013;
Annex II.II, 3.2)
Molecular characterisation (Reg. [EU] 503/2013; Annex II.II, 3.2.1)
Requirements in paragraph 3.2.1 of Annex II.II of Reg. (EU) 503/2013 are considered necessary in
LL applications.
Comparative analysis (Reg. [EU] 503/2013; Annex II.II, 3.2.2)
The goal of the targeted comparative compositional analysis in a LL application is to quantify
changes expected in the composition of the GMO, conﬁrming the hypothesis that triggered the
analysis. The applicant shall demonstrate that the targeted compositional analysis of the GMO has
been carried out in accordance with the considerations presented in this guidance (see Section 3.2.3.3
of this guidance).
Food and feed safety in relation to intake (Reg. [EU] 503/2013; Annex II.II, 3.2.3)
In a LL application, this aspect of the risk characterisation should consider the data generated to
estimate possible short- and long-term risks to human or animal health associated with the
consumption of food/feed containing the LL ingredient. Requirements described in paragraph 3.2.3 of
Annex II.II of Reg. (EU) 503/2013 are considered necessary, providing these are adapted to the
speciﬁc context of the LL situation under assessment.
Post-market monitoring will be considered on a case-by-case basis.
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3.2.5.2. The result of risk characterisation (Reg. [EU] 503/2013; Annex II.II, 3.3)
In accordance with the requirements of Annex II.II of Reg. (EU) 503/2013, the applicant should
ensure that the ﬁnal risk characterisation clearly demonstrates that the GMO does not impact the
safety and nutritional characteristics of the LL ingredient (where it is unavoidably, adventitiously
present at maximum 0.9%) to such an extent that the normal consumption of the LL ingredient would
be nutritionally disadvantageous for consumers or animals.
The applicant should clearly indicate what assumptions have been made during the risk assessment
in order to predict the probability of occurrence and severity of adverse effect(s) in a given population,
and the nature and magnitude of uncertainties associated with establishing these risks.
Information justifying the inclusion or not of a proposal for labelling in the application is not
required considering the scope of LL applications.
3.2.5.3. Cumulative risk assessment
The risk assessment of LL applications described in this guidance is carried out for a GMO present
at a predeﬁned maximum 0.9% exposure level per ingredient. In case of multiple LL applications for
GMOs showing similar traits, the possible cumulative contribution of the various GMOs to the
ingredient should be taken into consideration in the risk assessment, as required by the mandate (see
Section 1.1 of this guidance). For example, if a similar trait intended for improving nutrition is
expressed in different GMOs subject of different LL applications, the relative contribution to the
ingredient of each of these GMOs should be taken into account to allow an estimation of their total
contribution, via the addition of the respective trait-related constituent(s). Information from the
outcome of the targeted compositional analysis (see Section 3.2.3.3 of this guidance) of each of these
GMOs is relevant to establish the strategy to perform the cumulative assessment.
3.3. Environmental risk assessment
As mentioned in Reg. (EU) 503/2013, the ERA of GMOs or food/feed containing or consisting of
GMOs should be performed according to the principles outlined in Annex II to Directive 2001/18/EC on
the deliberate release into the environment of GMOs, and applicable GMO Panel Guidance Documents.
The GMO Panel therefore recommends applicants to follow the principles and approach outlined in the
GMO Panel Guidance Document on the environmental risk assessments of GM plants (EFSA GMO
Panel, 2010) and other applicable EFSA guidelines (i.e. EFSA, 2017) to determine the data
requirements for ERA of GM plants under LL situations.
ERAs conducted under LL situations should be case-speciﬁc (taking into account the biology of the
plant species, the intended trait(s), the potential receiving environments and interactions among all
three), and should begin with an explicit problem formulation where the GM plant is described using
existing knowledge, and potential hazards and exposure routes are identiﬁed (OECD, 2013; Roberts
et al., 2014). Taking this information into account, applicants should identify which areas of risk need
to be addressed and hence the data requirements to inform the risk assessment. Risk should then be
characterised by testing speciﬁc hypotheses about the likelihood and severity of adverse environmental
effects that may occur.
The problem formulation should focus on the following exposure pathways: (1) exposure of
microbial communities to recombinant DNA in the gastrointestinal tract of animals fed GM plant
material or recombinant DNA in faecal material (manure and faeces) of these animals; and (2)
accidental release into the environment of imported viable material from the GM plant during
transportation and processing.
In general, a comparative analysis of agronomic and phenotypic characteristics of the LL GM plant
to identify potential hazards is not considered mandatory under LL situations, representing a
derogation to Annex II requirements of Reg. (EU) 503/2013. However, such analysis may be needed
to support the ERA on a case-by-case basis depending on the persistence, invasiveness and
hybridisation potential of the LL GM plant.
4. Conclusions
This guidance indicates which scientiﬁc requirements of Annex II of Reg. (EU) 503/2013 are
necessary to conclude on the safety of applications covering the unintended and technically
unavoidable presence in food and feed of low level of GM plant material (0.9% or below per
ingredient) intended for markets other than in the EU.
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To this aim, a comprehensive characterisation of the transformation event and of its intended
effects should be performed. Not all the scientiﬁc requirements of the Annex II of Reg. (EU) 503/2013
aiming at identifying unintended effects are considered necessary on a routine basis, since the safety
and nutritional impact of these effects on the ingredient is considered limited in the context of
presence of a GM plant material at low level.
On a case-by-case basis, when a hypothesis for relevant compositional changes can be formulated,
a target compositional analysis is requested. The experimental design, selection of endpoints and data
analysis of such a targeted analysis would not need to follow all the scientiﬁc requirements of Annex II
of Reg. (EU) 503/2013. Comparative compositional studies performed according to Codex Alimentarius
could support such assessment.
The applicant needs to justify the approach followed and to indicate what assumptions have been
made during the risk assessment, as well as the nature and magnitude of uncertainties.
Both acute and repeated exposure scenarios should be envisaged. The possible cumulative
contribution to an ingredient from various genetically modiﬁed plants and derived products present at
low level and showing similar traits should be considered.
ERAs conducted under situations of presence at low levels should follow the principles and
approach outlined in the EFSA Guidance Document on the environmental risk assessments of GM
plants (EFSA GMO Panel, 2010) and other applicable EFSA guidelines.
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Glossary and Abbreviations
LL situation A situation where a GMO (i.e. a GM plant and/or its derived products or
food or feed use) not previously authorised in the EU is present at a level
of maximum 0.9% per ingredient in any food and/or feed, due to
adventitious or technically unavoidable circumstances. A LL situation can
occur from point of entry into the EU, through the food/feed production
processing chain, up to the food (or feed) portion consumed.
LL application An application for a GMO (and derived food/feed) at low levels (i.e. under
a LL situation), submitted under Reg. (EC) 1829/2003.
LL ingredient The mixture of the GMO subject of a LL application and the same plant
species and/or derived product, at the predeﬁned proportion of a
maximum of 0.9% and 99.1%, respectively.
Standard GMO application An application submitted under Reg. (EC) 1829/2003 for food/feed,
import and processing and assessed according to Reg. (EU) 503/2013
and relevant EFSA guidance documents (EFSA GMO Panel, 2010, 2011a).
ERA environmental risk assessment
GM genetically modiﬁed
GMO genetically modiﬁed organism
LL Low Level
LLP Low Level Presence
OECD Organisation for Economic Co-operation and Development
ORF open reading frame
RNAi ribonucleic acid interference
WG Working Group
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Appendix A – Principles of Codex Alimentarius on situations at low level
presence as compared to the terms of reference of the GMO Panel guidance
on the risk assessment of the presence at low level of genetically modiﬁed
plant material in imported food and feed under Regulation (EC)
No 1829/2003
Scope
– Codex Alimentarius (Codex Alimentarius, 2009, Annex 3) provides an approach for the risk
assessment of food. Instead, the GMO Panel guidance on LL is intended to cover the risk
assessment of food and feed under the frame of Reg. (EC) 1829/2003.
– Codex Alimentarius (Codex Alimentarius, 2009, Annex 3) considers only the dietary
exposure. In contrast, the GMO Panel guidance requested to cover all possible routes of
exposure of consumers/animals to the GMO in addition to the diet, in accordance with
Reg. (EC) 1829/2003.
– Codex Alimentarius (Codex Alimentarius, 2009, Annex 3) is applicable to situations of GMO
presence at low level either before or after these have occurred (a priori and a posteriori
assessment). Instead, the GMO Panel guidance is intended to support only the risk assessment
of situations of GMO presence at low level before these occur (a priori assessment).
– In contrast to Codex Alimentarius (Codex Alimentarius, 2009, Annex 3), the GMO
Panel guidance includes ERA considerations, as Reg. (EU) 503/2013 requires the ERA of GMOs
or food and feed containing, or consisting of, GMOs to be performed according to the
principles outlined in Annex II to Directive 2001/18/EC of the European Parliament and of the
Council of 12 March 2001 on the deliberate release into the environment of GMOs and
repealing Council Directive 90/220/EEC, and the applicable GMO Panel guidance (EFSA GMO
Panel, 2010).
Prerequisites to identify a low level presence situation
– Codex Alimentarius (Codex Alimentarius, 2009, Annex 3) recognises that an increasing
number of GMOs is undergoing authorisation and commercialisation at different rates in
different countries (asymmetric authorisations). As a consequence, LL situations may occur in
importing countries where the GMO has not yet been assessed according to Codex
Alimentarius (Codex Alimentarius, 2009). The Codex Alimentarius on such situations LLP
(Codex Alimentarius, 2009, Annex 3) stipulates that a GMO can only be considered for risk
assessment when present at low level if it has undergone a risk assessment according its
guidelines in a third country. In contrast, this mandate requires the GMO Panel to set
guidance for any GMO present at low level, independently of the existence of a third country
risk assessment.
Threshold deﬁnition
– Codex Alimentarius (Codex Alimentarius, 2009, Annex 3) proposes a risk assessment strategy
based on the expectation of a low exposure to the GMO, but does not deﬁne which amount
of the GMOs constitutes a LLP situation. Instead, in the GMO Panel guidance, the threshold
for situations of the presence at low levels of GMOs has been deﬁned by European
Commission as a level of maximum 0.9% of the GMO per ingredient in any food or feed
containing the same ingredient.
Possible dietary exposure scenarios in case of situations of GMO low level presence and risk
assessment strategies
Codex Alimentarius (Codex Alimentarius, 2009, Annex 3) distinguishes two categories of food
possibly subject of situations of low level presence; and associates these to two distinct dietary
exposure scenarios:
– food commodities small in particle size (e.g. grains, beans); these would constitute the most
frequent situation. In this case, any inadvertently commingled GM material is expected to be
present at low level in any individual serving of food, based on various assumptions (e.g.
commodities are derived from multiple plants, are sourced from multiple farms, and/or are
commingled during the food chain processing);
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– food commodities large in particle size (e.g. tomato, papaya), and commonly consumed
whole; these are expected to constitute a less frequent situation. In this case, each particle of
such food might constitute an entire consumed portion of the GMO.
The risk assessment strategy and methodology advocated by Codex Alimentarius (Codex
Alimentarius, 2009, Annex 3) differs for the two dietary exposure scenarios, with compositional data
(limited to key toxicants and allergens) required only for the second scenario. Instead, this GMO
Panel guidance is requested to cover an exposure scenario for which a GMO is present at a level of
maximum 0.9% per ingredient in the ﬁnal food or feed.
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